Insider Selling: Chimerix, Inc. (NASDAQ:CMRX) VP Sells 2,800 Shares of Stock

Chimerix, Inc. (NASDAQ:CMRX) VP David Jakeman sold 2,800 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $4.10, for a total transaction of $11,480.00. Following the completion of the transaction, the vice president now owns 149,287 shares in the company, valued at $612,076.70. This trade represents a 1.84 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Chimerix Stock Performance

Shares of CMRX opened at $3.94 on Friday. The firm has a market cap of $354.36 million, a PE ratio of -4.19 and a beta of 0.36. Chimerix, Inc. has a 52-week low of $0.75 and a 52-week high of $4.22. The business’s 50 day moving average price is $2.87 and its two-hundred day moving average price is $1.59.

Chimerix (NASDAQ:CMRX) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $1.26 million. During the same quarter in the previous year, the firm earned ($0.27) EPS. Research analysts predict that Chimerix, Inc. will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Chimerix

Institutional investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. grew its stake in shares of Chimerix by 154.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock valued at $2,846,000 after buying an additional 496,823 shares during the period. Peapod Lane Capital LLC acquired a new stake in Chimerix in the fourth quarter valued at approximately $2,626,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after acquiring an additional 138,098 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Chimerix during the second quarter worth approximately $137,000. Finally, Valeo Financial Advisors LLC grew its position in Chimerix by 78.8% in the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock valued at $509,000 after purchasing an additional 64,420 shares during the period. Institutional investors and hedge funds own 45.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on CMRX shares. HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Chimerix in a research note on Monday, December 30th. Wedbush reiterated an “outperform” rating and set a $6.00 price target on shares of Chimerix in a report on Tuesday, December 10th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.